CR1447 in Endocrine Responsive-HER2neg and TN-ARpos Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Adenocarcinoma|Breast Cancer
Interventions: DRUG: CR1447
Sponsor: Swiss Group for Clinical Cancer Research